drugset / Trial / NCT06803342
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Phase 2
Active not recruiting
200 enrolled
Albert B. Sabin Vaccine Institute
Biomedical Advanced Research and Development Authority · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults
Timeline
- Start
- 2025-06-26
- Primary completion
- 2027-02
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | cAd3-Sudan | Vaccine | 1e+11 unknown | Intramuscular |